Radioisotopes Research Today is a free monthly online journal that collates and summarizes the latest research about Radioisotopes, including details on radioimmunotherapy, radionuclides, procedures, hazards.

Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer.

Chen J, Wu H, Han D, Xie C

Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Dadao, 430030 Wuhan, People's Republic of China. lindaxcx@hotmail.com

To study the biodistribution of a new radioimmunoconjugate-131I-anti-VEGF monoclonal antibody (Sc-7269)-Dextran Magnetic Nanoparticles (DMN) in nude mice bearing human liver cancer where an external magnetic field was focused on, and to evaluate its therapeutic effects and safety. Tumor Growth Delay (TGD) and tumor inhibition rate were observed as antitumor effect. Peripheral white blood cells counts and the loss of body weight were tested as an indicator of systemic toxicity. The results suggests that the radioimmunotherapy of intratumoral injection of 131I-Sc-7269-DMN may be safe and efficient for the treatment of liver cancer. Furthermore, the radioimmunotherapy using DMN as a 'carrier system' may be a highly potential approach in the treatment of other kind of tumors.

Published 9 January 2006 in Cancer Lett, 231(2): 169-75.
Full-text of this article is available online (may require subscription).

© 2005-2008 Radioisotopes Research Today. All Rights Reserved.